| Market Capitalization (Millions $) |
32,771 |
| Shares
Outstanding (Millions) |
148 |
| Employees |
7,500 |
| Revenues (TTM) (Millions $) |
9,937 |
| Net Income (TTM) (Millions $) |
1,372 |
| Cash Flow (TTM) (Millions $) |
735 |
| Capital Exp. (TTM) (Millions $) |
190 |
Business Description
Company Profile: Biogen Inc.
Overview:
Biogen Inc. is a leading global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases, as well as other serious medical conditions. Established in 1978, Biogen has a long-standing commitment to transforming scientific discoveries into effective healthcare solutions that improve the lives of patients worldwide.
Core Focus Areas:
Biogen specializes in the treatment of:
- Neurological Disorders: The company is particularly known for its advancements in therapies for multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease.
- Oncology: Biogen develops therapies for various cancers, focusing on unmet medical needs and innovative treatment options.
- Immunology: The company is engaged in creating novel immunotherapies for autoimmune diseases.
Key Products:
Biogen has developed a robust portfolio of commercial products, which include:
- AVONEX® (Interferon beta-1a): A leading therapy for the treatment of relapsing forms of multiple sclerosis (MS).
- RITUXAN® (rituximab): A targeted therapy used to treat certain types of B-cell non-Hodgkin lymphomas (B-cell NHLs) and other autoimmune disorders.
- ZEVALIN® (ibritumomab tiuxetan): An innovative radioimmunotherapy for treating specific types of B-cell NHLs.
- AMEVIVE® (alefacept): Approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis indicating the need for systemic therapy.
Innovation and Research:
Biogen operates several research and development facilities around the globe, focusing on cutting-edge scientific advancements in biotechnology. The companys pipeline features numerous investigational therapies aimed at addressing significant medical challenges in neurology and beyond.
Commitment to Patients:
Biogen is deeply committed to patient access and support, providing resources and programs that help patients navigate their treatment journeys. The companys dedication to healthcare extends to partnerships with healthcare professionals and advocacy groups to enhance patient care and outcomes.
Sustainability and Ethics:
Biogen is also committed to sustainability in its operations, adhering to ethical practices that demonstrate a responsibility to the environment, communities, and stakeholders.
Conclusion:
As a trailblazer in the biotechnology field, Biogen Inc. continues to set new standards in patient care and innovation, driven by a mission to support individuals in their fight against debilitating diseases. With a strong portfolio and a commitment to research and development, Biogen is focused on transforming the landscape of healthcare.
Company Address: 225 Binney Street Zagreb 2142 City of Zagreb
Company Phone Number: 679-2000 Stock Exchange / Ticker: NASDAQ BIIB
|
1.11% 
70.72 %